US/UK/Canada

Share

Pick a time period -
Tags ( Active)

2bind and Dynamic Biosensors sign technology-service partnership

Munich, Germany, and Regensburg, Germany, 01 September 2022 – Dynamic Biosensors and 2bind, a Contract Research Organization (CRO), today announce that they have signed a technology-service partnership which will enable both companies to further help their customers to accelerate research. The collaboration will enable 2bind to integrate Dynamic Biosensors’ innovative heliX[®] system into its service portfolio, giving Dynamic Biosensors another highly experienced partner in the areas of certified services and beta-testing of future technologies.2bind is a highly respected CRO focused on

Goodly Innovations closes Series A+ financing enabling accelerated development & rollout of its AR (Augmented Reality) supported process guidance system for the pharmaceutical industry

Munich/Landshut, Germany, 7 April 2022 – Goodly Innovations, a software startup specialising in process digitalisation and the use of augmented reality (AR), today announced it has closed a seven-figure Series A+ financing round. Existing investors Bayern Kapital, the venture and growth capital company of the Free State of Bavaria, and BayBG Bayerische Beteiligungsgesellschaft were joined by a family office and a number of business angels. Goodly Innovations is developing and commericalising a system for digitising and managing complex processes using AR technology, significantly improving

Cytosurge launches cell line engineering services based on proprietary FluidFM technology

Zurich, March 30, 2022 – Cytosurge , a global leader in precision single cell manipulation, today announced the launch of FluidFM[®] CellEDIT, a CRISPR cell line engineering service  based on its FluidFM[®] technology. Genetically engineered cell lines have become an invaluable tool in biological research and drug discovery. Nobel-prize winning CRISPR technology has opened up multiple opportunities for generating genome-edited cell lines to be used as disease models, which help the understanding of the biology

R&D project by Cytosurge and the Laboratory of Biosensors and Bioelectronics at the Swiss Federal Institute of Technology receives funding by Innosuisse

Innosuisse is co-funding the collaboration to address a critical bottleneck in the research of pharmacology and the understanding of diseases by automating the creation and handling of single- and multi-cellular biological models in neuroscience.Zurich, January 18, 2022 – Cytosurge , a leading global provider for precision single cell manipulation, is delighted to announce that together with the Laboratory of Biosensors and Bioelectronics (LBB)  at the Swiss Federal Institute of Technology (ETH) in Zurich it has been awarded a

AniV8 announces oversubscribed pre-seed funding round

· Funding will accelerate development of wearable monitor to detect osteoarthritis-related pain in companion animals · Backed by experienced seed investors including Irrus Investments, Pro-Vet and Stonehaven Incubate · Seed financing planned for 2022 to further drive product development and commercialization · Investment by Pro-Vet enables for commercialization in China and other Asian countriesDelaware, US, 4 October 2021 – AniV8, a leading developer of clinical sensor technology to diagnose and monitor diseases affecting companion animals, today announced the completion of

Opterion Health strengthens its Management Team

Muttenz, Switzerland, 16 September 2021 – Opterion Health AG , a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant strengthening of its management team, including the appointments of Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been appointed Head of Quality and Ulrike Grimm Head of Project Management. Andreas Schmidt, whom Daniel Lustenberger succeeds as CFO, will continue to support Opterion Health as a partner.Opterion Health is

Anifera awarded seed funding for research from UK’s Centre for Innovation Excellence in Livestock (CIEL)

· Funding will enable Anifera to investigate efficacy of their leading compound to enhance antibiotic treatment for bovine mastitis, a significant economic and welfare challenge for the global dairy industry · Data will support development of a commercialisation plan for their leading compound, globally, with the goal of improving efficacy of older antibiotics and ultimately reducing overall antibiotic usage in livestockLondon, UK, 14 September 2021 – Anifera, a company focused on developing adjunct therapy to improve the efficacy of antibiotics used in animal health, today announced

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media